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The biological, clinical and social effects of alcohol abuse call for objective and specific biomarkers of 
alcohol-related diseases and early detection of alcohol consumers at risk. Alcohol abusers may exhibit 
several clinical and/or chemical changes. Changes in parameters such as gamma-glutamyltransferase 
(GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and mean corpuscular volume 
(MCV) may serve as biomarkers of chronic alcoholism. All available biomarkers have two drawbacks. 
The first is that they indicate adverse effects in a particular organ, but tell little about their aetiology. The 
second is that they are not sensitive enough to detect abuse before it results in organic impairment. The 
1990s have seen the introduction of a new diagnostic biomarker, carbohydrate-deficient transferrin (CDT). 
Reduced concentrations of this biomarker are found in serum after regular high alcohol intake. Relying 
on literature and their own clinical experience, the authors conclude that CDT seems to meet the clinical 
criteria of reliability and specificity.
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Early detection of excessive alcohol use is very 
important due to its harmful effects on a human 
organism and a person’s psychosocial life. It is not 
surprising that a number of scientists have persistently 
been searching for an ideal diagnostic biomarker that 
could confirm the diagnosis of alcohol abuse. Such 
an indicator should include clinical and biochemical 
parameters which would specifically correlate with 
the presence of ethanol or its metabolites in the 
organism, be directly related with the quantity 
of alcohol consumed, be susceptible enough to 
correlate the quantity of consumed alcohol and 
the psychosomatic risk, and finally, feature certain 
kinetics during abstinence (1, 2). However, no such 
biomarker has yet been discovered. Transferrin with a 
reduced carbohydrate share, carbohydrate-deficient 
transferrin (CDT) found in blood serum of examined 
persons comes the closest to meeting the required 
criteria (1).
Transferrin is a glycoprotein synthesised in the liver, 
and is responsible for the transport of iron in plasma. 
Transferrin carbohydrates are olygosacharides, 
linked to transferrin in two complex chains. Every 
chain contains bonds between N-acetylglucosamine, 
mannose, galactose and sialic acid. The terminal of the 
chain is concluded by a negatively charged sialic acid, 
which defines the isoelectric point (pI) of the protein. 
Various isoforms of transferrin can contain between 
0 and 5 sialic acids (asialo- to pentasialotransferrin). 
The most common isoform is the tetrasialotransferrin 
with the pI of 5.4.
The blood of persons who consume at least 60 g 
of pure alcohol per day (e. g. 750 ml of wine, 1,750 ml 
of beer or 180 ml of brandy) 14 days in a row, contains 
isoforms of transferrin with a reduced number of sialic 
acids (asialo-, disialo- and trisialotransferrin), called 
CDT. The methodology for determining the CDT 
content is based on the differences in charge between 
the desialised forms of transferrin. The formation of 
CDT is associated with the impact of acetaldehyde, 
the first metabolite of ethanol, on glycosiltransferase 
activity in the liver, which affects the transfer of the 
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sialic acid to the transferrin molecule. In turn, the liver 
produces transferrin molecules with the reduced share 
of carbohydrates, that is CDT, in addition to regular 
trasferrin.
More recent biomarkers of alcohol abuse include 
the assessment of the mitochondrial aspartate 
aminotransferase (mAST), serotonin metabolites, 
acetaldehyde and acetaldehyde adducts, as well as 
the application of tests for early detection of alcohol 
consumption (EDAC). However, none of these 
biomarkers meets all requirements. Human serum 
contains two AST isoenzymes: mAST and cytosolic 
AST (cAST). The enzyme activity in the serum of 
healthy persons mostly involves cAST, while in persons 
who consume too much alcohol the liver mitochondria 
are selectively damaged. This results in an increased 
activity of mAST. The proportion between mAST and 
overall AST activities helps to differentiate between 
alcohol-induced liver changes and changes of other 
aetiology (2).
Serotonin usually metabolises into 5-
hydroxytriptofol-3-acetic acid (5-HIAA) and 
5-hydroxytriptofol (5-HTOL). The major part is 
represented by the 5-HIAA metabolite. Alcohol intake 
tends to stimulate the metabolism of serotonin into 
5-HTOL. Elevated concentrations of this metabolite 
can be traced in blood six to fifteen hours after the 
alcohol levels return to normal (2).
Acetaldehyde is the first ethanol metabolite, but it 
is not considered a good biomarker of alcohol abuse, 
since it metabolises into acetate within five hours from 
alcohol intake. Forming Schiff bases with amines, 
acetaldehyde readily binds to a protein in an irreversible 
reaction, producing acetaldehyde-protein adduct. 
Many proteins generate adducts with acetaldehyde, 
among them albumins and haemoglobin. Abnormal 
blood concentrations of these adducts were found 
after acute alcohol intoxication, as well as after chronic 
alcohol abuse (2).
Early detection of alcohol consumption (the so 
called EDAC test) relies on the results of routine 
biochemical and haematological examinations 
(usually 35 parameters) analysed by the linear 
discriminant function (LDF) using the Statistical 
Package for the Social Sciences programme. The 
analysis yields a numerical value pointing to a heavy 
drinker or a person at risk of alcohol abuse (3-5).
Apart from the recent biomarkers mentioned 
above, diagnosing alcohol abuse should rely on the 
results of routine biochemical and haematological 
tests such as gamma-glutamyl transferase 
(GGT), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), high density level (HDL)-
cholesterol, and mean corpuscular volume (MCV), as 
well as on the concentrations of ethanol and methanol 
in blood (2, 6-10).
All liver disorders such as holestase and cyrrhosis 
of various origin, neoplasia and toxic damages caused 
by alcohol, drugs or tobacco are accompanied by 
increased GGT activity in serum. This enzyme is not 
limited only to the liver, but can also be found in the 
kidneys, pancreas and prostate. Normal serum GGT 
values in men are nearly 50 % higher than in women, 
mostly due to prostate GGT (11). A single excessive 
alcohol intake has no effect on GGT activity. However, 
in chronic alcohol consumption, the activity of the 
enzyme increases and varies from person to person 
(the sensitivity of the method is only 50 %) (9). The 
kinetics of increased GGT activity and the return to 
normal levels largely depend on how strong was the 
induction of the enzyme and significantly correlate with 
the liver disorder. A two to five week abstinence from 
alcohol usually suffices for GGT to return to normal 
activity (7, 9).
The first sign of the liver cell decay is the increase 
in catalytic activities of serum AST and ALT. It is well 
known that a liver disease can be caused by a variety 
of agents. Moreover, changes in other organs may also 
increase the levels of AST and ALT in serum. Therefore 
the activities of both enzymes are relatively unspecific 
for diagnosing alcoholism. In case of alcohol-related 
liver disease, only an activity ratio of AST:ALT higher 
than 2 is of diagnostic importance.
Research has shown that one of the nonspecific 
indicators of alcohol abuse is elevated HDL-
cholesterol. High concentrations of HDL-cholesterol 
in the serum may be indicative of chronic alcohol 
abuse (7 ,9).
Increased MCV can be due to the antagonistic 
effect of alcohol on folate. However, higher MCV also 
accompanies vitamin B12 or folic acid deficiencies, 
liver disease, some haematologic diseases, 
hypothyroidism, tobacco smoking or antiepileptic 
intake. If the increase in MCV levels is caused by 
alcohol drinking, it is reasonable to expect that the 
concentrations will return to normal values after three 
to six months of abstinence from alcohol (due to the 
corpuscle life expectancy) (7, 9).
The assessment of ethanol concentration in 
blood, urine or exhaled air is particularly useful in 
acute alcohol intoxication. Since alcohol disintegrates 
quickly after consumption, a one-time identification 
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of high ethanol blood levels tells very little of the 
frequency and duration of alcohol abuse. If alcohol 
concentrations in the blood are higher than the clinical 
assessment of drunkenness shows it is reasonable 
to suspect high alcohol tolerance and dependence 
(7, 9).
In addition to ethanol, the testing may include 
methanol as the most frequent accompanying 
alcohol found in almost all alcoholic beverages. 
Methanol absorption in the body is slightly slower 
than that of ethanol, and it can be found in all body 
fluids and organs. Alcoholdehydrogenase (ADH) is 
important for methanol metabolism. As ethanol shows 
greater affinity to the ADH-NAD complex, methanol 
is metabolised only after ethanol blood levels drop 
below 0.4 g/kg. Nevertheless, alcohol abstinence of 
approximately 24 hours suffices for the complete 
disintegration of methanol (12).
The aim of this study was to evaluate the 
usefulness of standard blood biomarkers in detecting 
alcohol abuse and in assessing its harmful effects in 
our patients performed during regular preventive 
medical check-ups. We especially focused on the 
applicability of carbohydrate-deficient transferrin in 
diagnosing alcohol abuse.
SUBJECTS AND METHODS
The control group (Group 1) consisted of 43 
healthy subjects (mean age 47.1 years, range 32-
56 years) who had never consumed alcohol. These 
control subjects were analysed for serum AST, ALT, 
GGT, and MCV, and their values kept within the normal 
range.
Group 2 consisted of 45 subjects (mean age 46.7 
years, range 39-54 years) who were suspect of alcohol 
abuse and dependence. Each subject was taken a 
blood sample for testing with biomarkers of alcohol 
abuse.
Catalytic activities of AST, ALT and GGT were 
determined according to procedures recommended 
by the International Federation of Clinical Chemistry, 
using a biochemical analyser BM/HITACHI 902 
produced by Roche Diagnostics Corp. (IN), USA, 
while the MCV results were obtained using the COBAS 
MICROS haematological analyser, also produced by 
Roche Diagnostics.
The per cent of CDT in blood serum was determined 
using the homogeneous immunologic method (Tina-
quant® %CDT, Roche Diagnostics). The set consisted 
of columns with ionic exchangers for the separation of 
transferrin isoforms and of reagents for turbidimetric 
determination of transferrin isoforms and the overall 
transferrin concentration. The analytical parameters 
for defining turbidimetric measurements of transferrin 
were set on the BM/HITACHI 902 biochemical analyser 
device according to manufacturer’s instructions. After 
determining separate isoforms of transferrin (CDT) 
and the overall transferrin concentration, the CDT 
percentage was calculated according to the formula 
defined by the reagent manufacturer.
Data were analysed using standard methods of 
parametric statistics. The differences between the 
mean values of individual groups were tested using the 
Statistical Package for the Social Sciences computer 
programme for variance analysis and Pearson’s 
correlation.
RESULTS
The ratability of %CDT determination expressed 
as relative standard deviation (RSD) was established 
by human serum (N=10 in a series) and commercial 
native control serums (N=10 in consecutive days) 
analyses (Table 1).
Table 1  Ratability of per cent carbohydrate-deficient transferrin (%CDT) 
determination in human serum and in control material
Sample Mean SD RSD  (%)
aHuman serum 12.2 0.729 6
bNative control serum
Level I 4.53 0.377 8.3
Level II 10.2 0.57 5.6
aIn series (N=10)
bOn consecutive days (N=10)
Table 2 shows the mean values of the measured 
parameters and variance analysis and Table 3 the 
relationships between CDT and other measured 
parameters. In Group 1, only one subject showed 
abnormal AST activity (over 0.60 µkat/L) and four 
subjects had the border %CDT values (between 5 
and 6).
In Group 2, only one GGT finding was within the 
normal range (below 0.62 µkat/L), and the highest 
measured activity was impressive 25.3 µkat/L. 
Activities of ALT and AST were within the normal range 
(<0.70 µkat/L and <0.60 µkat/L, respectively) in 21 
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subjects and 23 subjects, respectively, whereas MCV 
was normal in 15 subjects (<94 fL). In 17 subjects 
%CDT was below 5, in 11 between 5 and 6 and in 17 
above 6 (the highest was 12.1).
All biochemical parameters in Group 1 were within 
the normal limits, but in Group 2 they were considered 
pathological. The two groups show a statistically 
significant difference in means (P<0.001).
The percentages of CDT in both groups taken 
together show a statistically significant correlation with 
all measured parameters. If the correlation is assessed 
for group 1 only, it can be seen that there is none. 
Group 2, shows a significant correlation (P<0.01) 
between %CDT and AST and %CDT and MCV. The 
correlation between %CDT and GGT is weak, and no 
correlation is visible for %CDT and ALT.
DISCUSSION
In the last decade, a number of studies investigated 
the importance of %CDT as a biomarker of alcohol 
abuse. Due to the fact that its origin directly depends 
on ethanol or its metabolites, it has been considered 
of high diagnostic importance with sensitivity 73 % 
and specificity 96 % (11).
False positive %CDT was found in persons 
suffering from primary biliary cyrrhosis, chronic 
active hepatitis, genetic D-forms of transferrin, and 
carbohydrate-deficient glycoprotein syndrome. False 
negative results were found in persons who, before 
blood sampling, were had been consuming less than 
60 g of ethanol per day or had been consuming this 
daily quantity for less than two weeks (1). Since the 
increased CDT is independent of the liver status, 
determining %CDT helps to distinguish alcohol-
induced changes in the liver from changes of other 
origin (12-14).
This %CDT assessment in serum with the aim to 
ascertain alcohol abuse has been supported by the 
US Food and Drug Administration (FDA). In turn, US 
FDA refers to liver enzymes GGT, AST, and ALT, which 
have served as biochemical biomarkers of alcohol 
abuse for decades, as biomarkers of liver damage. It 
recommends that GGT, AST and ALT findings should 
be considered with %CDT results, which increases the 
diagnostic sensitivity from 73 % to 90 % (11).
In our study, we used a homogenous immunologic 
method with Roche reagents (Tina-quant® %CDT) to 
determine blood serum %CDT. The repeatability 
of %CDT determination corresponded to the 
recommendations of the reagent manufacturers.
The manufacturer explains the reference range 
as follows: in persons who abstain from alcohol or 
consume it in “normal” quantities, the values for 
%CDT are below 5. All the %CDT above 6 indicate 
that the person has been consuming more than 60 
g of ethanol for 14 days minimum. When abstinence 
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Table 2 Measured parameters in controls (Group 1) and subjects with alcohol abuse (Group 2)
Variable Group 1 Group 2
Variance analysis
F P
Gamma-glutamyltransferase (GGT) 0.284±0.113 3.99±5.67 18.322 0.000
Alanine aminotransferase (ALT) 0.312±0.168 0.841±0.653 26.353 0.000
Aspartate aminotransferase (AST) 0.279±0.058 0.654±0.447 28.959 0.000
Mean corpuscular volume (MCV) 90.1±3.572 94.8±7.37 24.783 0.000
Carbohydrate-deficient transferrin ( %CDT) 4.37±0.725 5.65±1.89 17.308 0.000
Results are presented as means ± standard deviations
Table 3 Correlation between per cent carbohydrate-deficient transferrin (%CDT) and other parameters measured in the examined subjects
Variable
Group 1 Group 2 All
r P r P r P
Gamma-glutamyltransferase (GGT) -0.092 0.558 0.280 0.063 0.388 0.000
Alanine aminotransferase (ALT) -0.109 0.485 0.166 0.307 0.334 0.002
Aspartate aminotransferase (AST) 0.117 0.462 0.468 0.002 0.571 0.000
Mean corpuscular volume (MCV) -0.202 0.193 0.693 0.000 0.575 0.000
r – Pearson correlation coefficient
Group 1 – control; Group 2 – subjects with alcohol abuse
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from alcohol is total, the values of %CDT are expected 
to reach the reference range in one or two months 
(half-life of approximately 15 days).
Roche Diagnostics has already prepared the 2nd 
generation of reagents for %CDT determination which 
are expected to increase the clinical sensitivity of the 
test. This means that the reference values range will 
also change.
Despite all the advantages of %CDT over classical 
laboratory tests (GGT, AST, ALT, and MCV), alcohol 
abuse assessment should not rely on %CDT alone. 
Research has shown that only a combination of several 
laboratory parameters can increase the diagnostic 
sensitivity and help the physician to determine alcohol 
abuse (8, 11). The diagnosis should be made by a 
physician who is trained to assess a variety of alcohol-
related diseases and damage to individual organs. 
The physicians usually apply four basic diagnostic 
methods (15, 16): case history, clinical check-up, 
laboratory tests, and psychiatric examination.
It is essential that the physician never forgets 
that the diagnosis of alcohol abuse or dependence 
is based on a well-prepared case history and physical 
check-up. Laboratory tests alone (biochemical, 
haematological, urine analysis), are insufficient, and 
they should serve to support case history and physical 
check-up of the patient. Biochemical parameters 
provide additional diagnostic material but they are not 
specific by themselves. In the identification process 
of alcohol abuse among the population they have 
a greater importance than placing the diagnosis of 
individual cases. These processes still do not provide 
a specific result in the group of alcohol-related health 
deficiencies (16).
Quite often, the diagnosis can be confirmed by a 
questionnaire, which can help to identify a number 
of clinical symptoms, obtain history data and data 
on the drinking habit. Some authors believe that 
80-90 % of patients answer truthfully. A well-known 
questionnaire is the Michigan Alcohol Screening Test 
(MAST). This questionnaire consists of 25 questions, 
most of them referring to complications caused by 
alcohol. It focuses on the patients’ perception of 
their own alcohol consumption (17). The second 
questionnaire in common use is the Severity Alcohol 
Dependence Questionnaire which focuses on the 
degree of alcohol abuse. The most common and 
simple questionnaire is the so called CAGE (C for 
cut down; A for annoyed; G for guilty; E for eye-
opener) which initiates the diagnostic procedure for 
potential alcoholism. The questionnaire consists of 
four questions and two positive answers is enough to 
be considered alcohol dependent (18). The Alcohol 
Use Disorder Identification Test (AUDIT) questionnaire 
is very practical in identifying alcohol abuse. It has the 
greatest overall validity in the population at large, and 
is more sensitive in populations with a low prevalence 
of alcoholism (such as Asian) and more effective in 
detecting hazardous and harmful drinking. Test 
sensitivity is 92 % and reliability 93 %; it is simple 
and takes but a few minutes (19).
The diagnostic procedure is usually concluded 
by an extensive psychiatric evaluation. The physician 
makes his final diagnosis on the basis of all tests 
performed, including the opinion of the psychiatrist. 
If a patient is diagnosed alcohol abuse/dependence, 
she or he is immediately invited to enter a recovery 
programme.
CONCLUSION
The carbohydrate-deficient transferrin (CDT) is 
a relatively new biochemical parameter. Despite the 
fact that it does not meet all the criteria for an ideal 
biomarker of alcohol abuse, it is still recommended in 
diagnosing alcohol abuse, in combination with other 
laboratory tests. Companies producing reagents 
for determining %CDT in blood serum are trying to 
develop such a reagent mix that would increase the 
clinical sensitivity of the test. Literature on CDT as an 
indicator of alcohol abuse suggests that higher clinical 
sensitivity and standardised laboratory procedures will 
increase the diagnostic value of blood serum %CDT.
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Saetak
BIOKEMIJSKI POKAZATELJI U KRVI UIVALACA ALKOHOLA
Biološka, klinièka i socijalna stanja alkoholièara veæ dugo iziskuju objektivne i specifiène pokazatelje 
poremeæaja uzrokovanih uivanjem alkohola u svrhu što ranijeg otkrivanja riziènih uivalaca. Uivaoci 
prekomjernih kolièina alkohola mogu pokazivati nekoliko klinièko-kemijskih promjena od kojih se neke 
upotrebljavaju kao pokazatelji alkoholizma. To su ponajprije promjene u aktivnostima jetrenih enzima 
gama-glutamiltransferaze (GGT), aspartat aminotransferaze (AST) i alanin aminotransferaze (ALT) te 
promjene srednjeg volumena eritrocita (MCV). Svi ti pokazatelji imaju dvije slabe strane. S jedne strane, 
mogu odraavati poremeæaj ili bolest odreðenog organa s nepouzdanom specifiènošæu prepoznavanja 
etiologije bolesti. S druge strane, nisu dovoljno osjetljivi za otkrivanje kroniènog alkoholièara prije nastajanja 
organskih komplikacija. Tijekom posljednjeg desetljeæa uveden je u dijagnostiku kroniènog alkoholizma 
novi biokemijski pokazatelj snieni ugljikohidratni transferin (carbohidrate deficient transferrin, CDT). To 
je glikoprotein koji prenosi eljezo u tijelu i koji se stvara i oslobaða iz jetre. Iako razlozi još nisu sasvim 
rasvijetljeni, u osoba koje redovito uivaju veæe kolièine alkohola koncentracija snienog ugljikohidratnog 
transferina u serumu redovito je povišena.
U radu su dani odabrani relevantni literaturni podaci o biokemijskim pokazateljima uivanja alkohola i 
dijagnosticiranja kroniènog alkoholizma. Usto, autori su i sami procjenjivali do koje mjere uobièajeni 
krvni biopokazatelji alkohola odraavaju štetne uèinke uivanja alkoholnih piæa u skupini vlastitih ispitanika 
tijekom periodièkih medicinskih pregleda. Pritom su se posebno usredotoèili na novi biokemijski parametar 
postotak CDT-a (%CDT).
Na temelju pregleda literaturnih podataka i vlastitog opaanja, autori su zakljuèili da %CDT kao biopokazatelj 
alkohola u krvi u velikoj mjeri udovoljava postavljenim klinièkim kriterijima pouzdanosti i specifiènosti.
KLJUÈNE RIJEÈI: alanin aminotransferaza, aspartat aminotransferaza, gama-glutamiltransferaza, 
jetreni enzimi, snieni ugljikohidratni transferin, srednji volumen eritrocita 
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